Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration

• Jérémy Lourenco,
• Gilles Peytavin,
• Véronique Avetttand-Fenoel,
• Minh-Patrick Le,
• Claire Rouzaud,
• Fanny Lanternier,
• Caroline Charlier-Woerther,
• Fatima Touam,
• Carole Louisin,
• Olivier Lortholary,
• Claudine Duvivier

Affiliations

Jérémy Lourenco

Necker Hospital, Infectious Diseases Department, Paris, France

Gilles Peytavin

Bichat-Claude Bernard Hospital, Pharmaco-Toxicology Department, Paris, France/Université Paris Diderot University, Sorbonne Paris Cité, IAME, INSERM UMR 1137, France

Véronique Avetttand-Fenoel

Necker-Enfants malades University Hospital, Clinical Microbiology Department, Paris, France

Minh-Patrick Le

Bichat-Claude Bernard Hospital, Pharmaco-Toxicology Department, Paris, France/Université Paris Diderot University, Sorbonne Paris Cité, IAME, INSERM UMR 1137, France

Claire Rouzaud

Necker Hospital, Infectious Diseases Department, Paris, France

Fanny Lanternier

Necker Hospital, Infectious Diseases Department, Paris, France

Caroline Charlier-Woerther

Necker Hospital, Infectious Diseases Department, Paris, France

Fatima Touam

Necker Hospital, Infectious Diseases Department, Paris, France

Carole Louisin

Necker Hospital, Infectious Diseases Department, Paris, France

Olivier Lortholary

Necker Hospital, Infectious Diseases Department, Paris, France

Claudine Duvivier

Necker Hospital, Infectious Diseases Department, Paris, France